Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma
Adding immunotherapy and targeted drugs to TACE significantly reduces treatment resistance and improves survival in advanced liver cancer, suggesting it may become a new standard treatment.
Authors
- Hongchao Jiao (ORCID: https://orcid.org/0000-0001-6022-3490)
- Junxin Li (ORCID: https://orcid.org/0000-0001-9798-5456)
- Zhengang Zhang (ORCID: https://orcid.org/0000-0003-3811-0865)
- Yan Xu (ORCID: https://orcid.org/0000-0002-9596-2979)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.5306/wjco.v16.i8.109419
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32